Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Jurnal Bios Logos
Rattu, Ferencia
Unknown Affiliation
Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Gene Editing with CRISPR-Cas9 Technology for Hepatitis B Virus: A Literature Review Rattu, Ferencia
JURNAL BIOS LOGOS Vol. 15 No. 3 (2025): JURNAL BIOS LOGOS
Publisher : Universitas Sam Ratulangi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35799/jbl.v15i3.65836

Abstract

Hepatitis B Virus (HBV) is a global problem with a significant impact on morbidity and mortality rates that are expected to continue to increase if no further treatment is carried out. HBV is caused by the Hepatitis virus type B, which until now has no medical therapy that can eliminate HBV. The latest developments referring to gene editing for genetic and non-genetic diseases are clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9. CRISPR-Cas9 appears with a promising approach with solutions to various disease disorders. CRISPR-Cas9 with DNA editing by Cas9 endonuclease, which is guided by the RNA sequence is able to pair with the target base sequence. The purpose of this paper is to examine the effectiveness and potential of the gene editing method with CRISPR-Cas9 as a therapy for Hepatitis B disease. The writing method is a Literature Review with databases obtained through Google Scholar, PubMed, and ScienceDirect. Various studies and methods have been developed to improve the success of CRISPR-Cas9. Off-target effects are detected to reduce the risk of CRISPR-Cas9. The results show that CRISPR-Cas9 can inhibit HBV replication in vitro and in vivo. Therefore, the technology shows much-needed potential for eradicating the hepatitis B virus. However, further studies are needed to determine its safety and effectiveness as a hepatitis B therapy.
Co-Authors